Table 1.
Patient demographics in entire cohort and in the training, test and validation sets
| Missing | Overall | TRAIN SET | VALID SET | TEST SET | ||
|---|---|---|---|---|---|---|
| n | 287 | 199 | 44 | 44 | ||
| Age, mean (SD) | 0 | 55.7 (17.4) | 55.2 (17.1) | 59.0 (19.3) | 54.7 (16.7) | |
| Sex, n (%) | F | 0 | 122 (42.5) | 81 (40.7) | 25 (56.8) | 16 (36.4) |
| M | 165 (57.5) | 118 (59.3) | 19 (43.2) | 28 (63.6) | ||
| Tumor Size, median [Q1,Q3] | 0 | 9.0 [6.1,12.0] | 9.0 [6.2,11.8] | 9.0 [6.7,12.1] | 8.4 [5.7,13.0] | |
| Tumor Depth, n (%) | Superficial | 0 | 28 (9.8) | 23 (11.6) | 2 (4.5) | 3 (6.8) |
| Deep to fascia | 259 (90.2) | 176 (88.4) | 42 (95.5) | 41 (93.2) | ||
| Tumor Grade, n (%) | Low Grade | 0 | 21 (7.3) | 16 (8.0) | 2 (4.5) | 3 (6.8) |
| High Grade | 266 (92.7) | 183 (92.0) | 42 (95.5) | 41 (93.2) | ||
| Tumor Volume (cm^3), median [Q1,Q3] | 0 | 284.1 [82.4,694.3] | 292.5 [84.1,668.3] | 284.6 [81.8,830.6] | 250.3 [77.3,757.9] | |
| Follow up Time, median [Q1,Q3] | 0 | 1511.0 [819.0,2680.0] | 1577.0 [821.5,2741.0] | 1413.5 [729.2,2307.2] | 1423.0 [835.0,2529.5] | |
| Location, n (%) | Axial | 0 | 40 (13.9) | 27 (13.6) | 8 (18.2) | 5 (11.4) |
| Lower Extremity | 194 (67.6) | 136 (68.3) | 31 (70.5) | 27 (61.4) | ||
| Upper Extremity | 53 (18.5) | 36 (18.1) | 5 (11.4) | 12 (27.3) | ||
| Chemo (Neoadjuvant), n (%) | False | 0 | 193 (67.2) | 131 (65.8) | 30 (68.2) | 32 (72.7) |
| True | 94 (32.8) | 68 (34.2) | 14 (31.8) | 12 (27.3) | ||
| RT Type, n (%) | Pre-op | 0 | 132 (46.0) | 96 (48.2) | 16 (36.4) | 20 (45.5) |
| Post-op | 155 (54.0) | 103 (51.8) | 28 (63.6) | 24 (54.5) | ||
| Margin, n (%) | Negative (R0) | 1 | 259 (90.6) | 181 (91.0) | 41 (93.2) | 37 (86.0) |
| R1 | 26 (9.1) | 17 (8.5) | 3 (6.8) | 6 (14.0) | ||
| R2 | 1 (0.3) | 1 (0.5) | ||||
| Length of Surgery, median [Q1,Q3] | 0 | 3.5 [2.5,5.5] | 3.5 [2.5,5.8] | 3.4 [2.5,5.1] | 3.2 [2.0,5.5] | |
| Necrosis, median [Q1,Q3] | 13 | 0.3 [0.1,0.7] | 0.3 [0.1,0.7] | 0.3 [0.1,0.8] | 0.3 [0.1,0.7] | |
| Vital Status, n (%) | Dead | 0 | 201 (70.0) | 139 (69.8) | 32 (72.7) | 30 (68.2) |
| Alive | 86 (30.0) | 60 (30.2) | 12 (27.3) | 14 (31.8) | ||
| Local Recurrence, n (%) | No | 0 | 259 (90.2) | 180 (90.5) | 39 (88.6) | 40 (90.9) |
| Yes | 28 (9.8) | 19 (9.5) | 5 (11.4) | 4 (9.1) | ||
| Distant Mets, n (%) | No | 0 | 176 (61.3) | 118 (59.3) | 28 (63.6) | 30 (68.2) |
| Yes | 111 (38.7) | 81 (40.7) | 16 (36.4) | 14 (31.8) |
Breakdown of train, test and val sets. Tumor Grade: Grade is based on the final pathology report. Low Grade = Grade 1. High Grade = Grade 2, 3, or dedifferentiated. The 21 Low Grade sarcomas include 17 myxoid liposarcomas with round cell component <5%, two extraskeletal myxoid chondrosarcomas and two solitary fibrous tumors.